FDA Drug Diversion Act
Proposed rule for state regulation of drug wholesalers is expected to be available within the next two weeks, FDA said. The guideline proposes minimum standards for storage and handling, record keeping, and licensing. States will use the guidelines as a basis for developing their own regulations. Wholesalers must be licensed by the state two years after FDA publishes the final rule, the agency said. In addition, a guidance letter to industry on implementation of the act is expected to be available the week of Aug. 1 ("The Pink Sheet" July 25, T&G-1).
You may also be interested in...
Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.
GlaxoSmithKline has discontinued treatment with its ICOS agonist feladilimab in the Phase II INDUCE-3 trial upon the recommendation of the study’s data monitoring committee, another setback for the big pharma’s plans to become a major force in the cancer therapy area.
Forecasting up to a dozen complex generic launches by Teva in the US in 2021, executive vice-president for North America commercial Brendan O’Grady said Teva was continuing to push for changes to boost approval rates ahead of GDUFA III next year.